Effect of Fingolimod-Treatment on Blood Lipid Profiles of Multiple Sclerosis Patients

Borodulin K, Vartiainen E, Peltonen M, Jousilahti P, Juolevi A, Laatikainen T, Männistö S, Salomaa V, Sundvall J, Puska P (2015) Forty-year trends in cardiovascular risk factors in Finland. Eur J Pub Health 25(3):539–546 Epub 2014 Nov 24 Huang K, Li SQ, Wang WJ, Liu LS, Jiang YG, Feng PN, Wang YQ, Wang SM (2012) Oral FTY720 adminstration induces immune tolerance and inhibits early development of atherosclerosis in apolipoprotein E-deficient mice. Int J Immunopathol Pharmacol 25(2):397–406 Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group (2010) A placebo-controlled trial of oral fingolimod. N Engl J Med 362(5):387–401 Epub 2010 Jan 20 Klingenberg R, Nofer JR, Rudling M, Bea F, Blessing E, Preusch M, Grone HJ, Katus HA, Hansson GK (2007) Dengler TJ (2007) sphingosine-1-phosphate analogue FTY 720 causes lymphocyte Redistribution and hypercholesterolemia in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 27(11):2392–2399 Epub 2007 Aug 30 Nofer JR, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, van Berkel T, Assmann G, Biessen EA (2007) FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of early atherosclerosis in low-density lipoprotein-deficient mice. Circulation 115:501–508 Epub 2007 Jan 22 Simula S, Laitinen T, Laitinen, T.M., Tarkiainen T, Hartikainen, J.E.K., Hartikainen P (2015) Effects of three months fingolimod therapy on heart rate. J Neuroimmune pharm 10:651–654. Epub 2015 June 20.